Risk factor
Resilient to price shocks
Profitability factor
Good growth
About
Medicover AB (publ), established in Stockholm, Sweden in 1995, operates as a comprehensive provider of healthcare and diagnostic services throughout a dozen countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. The company's operations are distinctly categorized into two segments: Healthcare Services and Diagnostic Services. Within its Diagnostic Services arm, Medicover performs an extensive array of laboratory analyses. These span various specialties, encompassing tests for allergies and autoimmune conditions, infectious agents (bacteriology, parasitology, microbiology), biochemical and immunological markers, blood grouping and transfusion requirements, tumor detection, clinical chemistry, cellular and tissue pathology (cytology, haematology, histopathology), human genetics, hygiene, molecular biology, and pharmacological/toxicological screenings. This substantial diagnostic infrastructure includes 97 clinical laboratories, 733 blood collection points, and 26 specialized clinics, operational across 10 of its countries of presence. Complementing this, the Healthcare Services division features a broad network comprising 117 medical clinics, 20 fertility centers, 52 dental practices, 25 hospitals, and 25 fitness facilities. Medicover caters to a diverse clientele, serving corporate clients, private individuals, direct patients, and public sector payers.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E
Target Price
The average target price of MCOV-B.ST is 245 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in